Nephrogenic systemic fibrosis: Non-gadolinium options for the imaging of CKD/ESRD patients

Seminars in Dialysis

Volumn 21, Issue 2, 2008, Pages 160-165

  Dawson, Peter ^a   Punwani, Shonit ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; DRUG CONTRAINDICATION; FIBROSIS; HUMAN; METHODOLOGY; PATHOLOGY;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 40849087916     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00401.x     Document Type: Article

References (49)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit P : Scleromyxoedema-like cutaneous diseases in renal dialysis patients. Lancet 356 : 1000 1001, 2000
2. Evenepoel P, Zeegers M, Segaert S, Claes K, Kuypers D, Maes B, Flamen P, Fransis S, Vanrenterghem Y : Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 49 : 469 473, 2004
3. Cowper SE, Boyer PJ : Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8 : 151 157, 2006
4. Ting WW, Stone MS, Madison KC, Kurtz K : Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 : 903 906, 2003
5. Grobner T : Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104 1108, 2006
6. Thomsen HS : Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 : 2619 2621, 2006
7. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS : Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 : 2359 2362, 2006
8. DeHoratius DM, Cowper SE : Nephrogenic system fibrosis: an emerging threat among renal patients. Semin Dial 19 : 191 194, 2006
9. Bongartz G : Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? Magn Reson Mater Phys 20 : 57 62, 2007
10. Pedersen M : Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Res Imaging 25 : 881 883, 2007
11. Lin S-P, Brown JJ : MR contrast agents: physical and pharmacological basics. J Magn Res Imaging 25 : 884 899, 2007
12. Thomsen HS, Morcos S, Dawson P : Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61 : 905 906, 2007
13. Boyd AS, Zic JA, Abraham JL : Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 : 27 30, 2007
14. High WA, Ayers RA, Chandler J, Zito G, Cowper SE : Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 : 21 26, 2007
15. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett Al, Djamali A : Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 : 148 157, 2007
16. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA : Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 : 586 592, 2007
17. Cowper SE : Nephrogenic Fibrosing Dermopathy [NFD/NSF website - 2001-2006]. http://www.icnfdr.org, accessed December 8, 2007
18. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_P AGE&useSecondary=true&ssDocName=CON2030229&ssTargetNodeId=221, accessed December 8, 2007
19. Committee for Medicinal Products for Human Use CHMP : http://www.emea.europa.eu/htms/general/contacts/CHMP/CHMP.html. Committee of The European Medicines Agency (EMEA)
20. FDA : http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222. htm Dec 222006, May 23 2007 http://www.fda.gov/cder/drug/infopage/gcca/default. htm
21. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/MRSafety/ recommendations_gadolinium-based.aspx
22. http://www.esur.org/Nephrogenic_Fibrosis.39.0.html
23. ISMRM : http://www.ismrm.org
24. ESMRMB : http://www.esmrmb.org
25. Thomsen HS : Gadolinium contrast media for radiographic examinations. In : Baert AL, Sartor K (eds). Contrast Media. Safety Issues and ESUR Guidelines. Berlin and Heidelberg : Springer, 2006 : 117 118
26. Gray ML, Burstein D, et al. : Biochemical (and functional) imaging of articular cartilage. Semin Musculoskelet Radiol 5 : 329 343, 2001
27. Mikulis DJ, Roberts TP : Neuro MR: protocols. J Magn Reson Imaging 26 : 838 847, 2007
28. Colagrande S, Carbone SF, et al. : Magnetic resonance diffusion-weighted imaging: extraneurological applications. Radiol Med 111 : 392 419, 2006
29. Le Bihan D : The 'wet mind': water and functional neuroimaging. Phys Med Biol 52 : R57 R90, 2007
30. Blitstein MK, Tung GA : MRI of cerebral microhemorrhages. AJR Am J Roentgenol 189 : 720 725, 2007
31. Filippi M, Rocca MA : Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 4 : 401 413, 2007
32. Ceelen W, Smeets P, et al. : Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. Int J Radiat Oncol Biol Phys 64 : 1188 1196, 2006
33. Vincensini D, Dedieu V, et al. : Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magn Reson Imaging 25 : 293 302, 2007
34. Yekeler E, Danalioglu A, et al. : Crohn disease activity evaluated by Doppler ultrasonography of the superior mesenteric artery and the affected small-bowel segments. J US Med 24 : 59 65, 2005
35. Krumme B : Renal Doppler sonography - update in clinical nephrology. Nephron Clin Pract 103 : c24 c28, 2006
36. Anderson CM, Saloner D, et al. : Assessment of carotid artery stenosis by MR angiography: comparison with x-ray angiography and color-coded Doppler US. AJNR Am J Neuroradiol 13 : 989 1003, discussion 1005 1008, 1992
37. De Cobelli F, Cappion S, et al. : Noninvasive imaging of the abdominal vessels. Rays 26 : 269 276, 2001
38. D'Onofrio M, Mansueto G, et al. : Doppler US and contrast-enhanced magnetic resonance angiography in assessing carotid artery stenosis. Radiol Med 111 : 93 103, 2006
39. Mikkonen RH, Kreula JM, et al. : Reproducibility of Doppler US measurements. Acta Radiol 37 : 545 550, 1996
40. Mikkonen RH, Kreula JM, et al. : Peak systolic velocity, resistance index and pulsatility index. Variations in measuring a pre-recorded videotape. Acta Radiol 38 (4 Pt 1 598 602, 1997
41. Mikkonen RH, Kreula JM, et al. : Reliability of Doppler US in follow-up studies. Acta Radiol 39 : 193 199, 1998
42. Quaia E : Contrast-specific US techniques. Radiol Med 112 : 473 490, 2007
43. Quaia E : Microbubble US contrast agents: an update. Eur Radiol 17 : 1995 2008, 2007
44. Kaul S : Microbubbles and US: a bird's eye view. Trans Am Clin Climatol Assoc 115 : 137 148, 2004
45. Cosgrove D : US contrast agents: an overview. Eur J Radiol 60 : 324 330, 2006
46. Rubaltelli L, Corradin S, et al. : Automated quantitative evaluation of lymph node perfusion on contrast-enhanced sonography. AJR Am J Roentgenol 188 : 977 983, 2007
47. Wink MH, Wijkstra H, et al. : US imaging and contrast agents: a safe alternative to MRI? Minim Invasive Ther Allied Technol 15 : 93 100, 2006
48. Jakobsen JA, Oyen R, et al. : Safety of US contrast agents. Eur Radiol 15 : 941 945, 2005
49. Piscaglia F, Bolondi L : The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. US Med Biol 32 : 1369 1375, 2006